CBLI News and Press, Cleveland BioLabs Inc.

Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc." New Corporate Name and Updated Stock Ticker Symbol to Showcase Company's Post-Merger Transformation and Focus on Restoring Immune Health PR Newswire FORT COLLINS, Colo. , Aug. 31...

Start Time: 08:30 End Time: 08:49 Cytocom, Inc. (CBLI) Q2 2021 Earnings Conference Call August 16, 2021, 08:30 AM ET Company Participants Michael Handley - President and CEO Peter Aronstam - CFO Taunia Markvicka - COO Nichol Ochsner - SVP, IR and Corporate Communications Conference Call Parti...

Cytocom, Inc. Second Quarter 2021 Financial Results Conference Call Replay Available Via Webcast Audio archive for the event may be accessed from the "Investors" section of the Cytocom website PR Newswire FORT COLLINS, Colo. , Aug. 16, 2021 /PRNewswire/ -- ...

Cytocom, Inc. Reports Second Quarter 2021 Financial Results -All-stock merger transaction between legacy Cleveland BioLabs and legacy Cytocom recently completed; Cytocom, Inc. common stock trading on Nasdaq as "CBLI"- -Well financed allowing multiple clinical programs that c...

Cytocom, Inc. and La Jolla Institute for Immunology Announce Five-Year Research Alliance Agreement Cytocom to fund research in cancer, autoimmune and inflammatory conditions, and infectious diseases and applications to clinical-stage therapies Research to accelerate immune-m...

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference Mike K. Handley, President and CEO, will participate as featured panelist PR Newswire FORT COLLINS, Colo. , Aug. 11, 2021 /PRNewswire/ -- Cytoco...

Cytocom, Inc. to Report Second Quarter 2021 Financial Results Executive Management to Host Conference Call on Monday, August 16th at 8:30 a.m. ET PR Newswire FORT COLLINS, Colo. , Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading bioph...

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19 Patient enrollment in Phase 3 pediatric Crohn's disease trial expected to initiate by year-end 2021; End-of-Phase 2 meeting successfully completed in July E...

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs PR Newswire FORT COLLINS, Colo. , Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on imm...

Gainers: Exicure (NASDAQ:XCUR) +38%, Infinity Pharmaceuticals (NASDAQ:INFI) +26%, Ra Medical Systems (NYSE:RMED) +22%, Galmed Pharmaceuticals (NASDAQ:GLMD) +22%, Lava Therapeutics (NASDAQ:LVTX) +18%. Losers: TG Therapeutics (NASDAQ:TGTX) -24%,...